Genmab

	14/9 13:16 af E L	and another one, this time we are involved
	14/9 13:15 af E L	money is for free,they'll never run out of it ;-)
	14/9 13:00 af nohope	Fuck - BPx will run out of money before we get a decent +110 % offer for GEN.
	14/9 12:56 af E L	another deal- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations (link) SGEN up 17% pre-market
	14/9 12:35 af gentogen	Thanks EL. Sounds good: "an oral presentation and live Q&A of the latest data from the Phase 1 dose escalation study investigating amivantamab " (from your link)
	14/9 11:18 af StockBull	Enig Helge 8:31. Men husk på aktiemarkedet er som regel 6-9 måneder foran så det kunne tyde på markeded mener vi er over det værste. Så umidlbart tror jeg man skal supplere til den langsigtede beholdning på de retracements som kommer jævnligt
	14/9 08:59 af E L	Janssen to Present Key Data from Across Its Expansive Oncology Portfolio at ESMO 2020 Virtual Congress - Safety and efficacy data from the Phase 1 CHRYSALIS study exploring amivantamab in combination with lazertinib in patients with advanced EGFR-mutated NSCLC (link)
	14/9 08:51 af E L	will be interesting to see what valuations do this week for other biotechs with ADC's in their portfolio after the Immunicum news...
	14/9 08:31 af Helge Larsen/PI-redaktør	Vi skal først have overstået alt det med med coronavirus og dens senfølger på økonomien.
	14/9 07:36 af StockBull	Beder man Nikolaj Schmidt sætte en tidsramme på opsvinget, vurderer han, at vi står over for fem til otte år med positiv vækst, før man igen skal frygte en decideret recession som den, der ramte den globale økonomi i første og andet kvartal i år.
	14/9 07:35 af StockBull	Morn :-) Globalt opsving (link)
	14/9 07:01 af Helge Larsen/PI-redaktør	Vincent Rajkumar @VincentRK · 2 t 4 key slides from my talk on “How I Treat Newly Diagnosed Myeloma” at(link)
	14/9 06:58 af transalp	Go morgen .. :)
	14/9 06:48 af bibob	God morgen. :-)
	14/9 06:43 af Helge Larsen/PI-redaktør	God morgen. :-)
	13/9 21:27 af Helge Larsen/PI-redaktør	Test
	12/9 10:21 af Stroka	Den Twitterundersøgelse har indtil videre Dara som vinder. :-)
	12/9 08:10 af Helge Larsen/PI-redaktør	God morgen. :-)
	12/9 08:08 af transalp	Go morgen. :)
	12/9 06:34 af Helge Larsen/PI-redaktør	Se svar i Twittertråden og følg den løbende: Vincent Rajkumar @VincentRK Question for hem/onc docs: Newly Diagnosed AL Amyloidosis not in VGPR following frontline ASCT (No induction was given before ASCT). What’s your regimen of choice?(link)
	12/9 06:20 af Helge Larsen/PI-redaktør	God morgen. :-)
	11/9 20:33 af Helge Larsen/PI-redaktør	Vor egen tekniske analyse er her: (link)
	11/9 20:32 af Helge Larsen/PI-redaktør	Enhver har kunnet se denne udvikling i den seneste tid.
	11/9 20:31 af Helge Larsen/PI-redaktør	Det er blot en kortsigtet teknisk analyse: (link)

	11/9 20:18 af Klarussen	Aktieugebrevet: Genmab begynder at vise svaghedstegn
	11/9 20:17 af Klarussen	(link)
	11/9 18:53 af E L	Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis (link)
	11/9 15:29 af E L	traitor ;-)
	11/9 15:05 af Sukkeralf	Jep - if Lave Therapeutics goes to market I think I would throw some money after PP
	11/9 15:01 af E L	yes, and his name still regularly shows up in publications together with Genmab researchers
	11/9 14:59 af Sukkeralf	Old Genmab guy
	11/9 14:58 af Sukkeralf	Paul Parren, CEO of the γδ T cell-engaging bispecific company Lava Therapeutics, is watching this space. “I like bispecifics a lot, and I also like trispecifics a lot,” he says
	11/9 14:47 af E L	Trispecific antibodies take to the clinic -mentions the Sanofi CD3xCD28xCD38 - (link)
	11/9 14:14 af Legolas23	Nice one :-)
	11/9 13:36 af Sukkeralf	(link)
	11/9 13:36 af Sukkeralf	Ocrevus
	11/9 11:29 af E L	Building on BCMA-Directed Therapies in Multiple Myeloma (link)
	11/9 11:27 af E L	i am sure an awareness campaign will be part of the JNJ marketing strategy . There are probably more -unidentified- patients with amyloidosis
	11/9 11:26 af E L	The problem with amyloidosis is that it is often not recognised immediatley as amyloidosis ; it often comes through other doctors after hearth or renal failure if i understand correctly
	11/9 11:24 af E L	Genmab annual report p 26 -3,000-4,000 approximate number of new cases diagnosed annually, making AL amyloidosis the most common type of amyloidosis in the U.S - An estimated 16,000 people in the United States suffer from amyloidosis. - 12-15% of multiple myeloma patients develop light chain (AL) amyloidosis.
	11/9 11:17 af gentogen	So this is very good news for patients
	11/9 11:15 af gentogen	(link)
	11/9 11:15 af gentogen	Extrapolating from these data, there were at least 12 000 adults in the United States living with AL amyloidosis in 2015
	11/9 11:14 af gentogen	Using health care claims databases, our analysis indicates that the adjusted (unadjusted) prevalence of AL amyloidosis increased significantly from 20.1 (15.5) cases per million in 2007 to 50.1 (40.5) cases per million in 2015, an annual percentage change of 12% (11.9%)
	11/9 11:11 af E L	it is a repeat of the ASCO data
	11/9 11:10 af E L	Genmab @Genmab We are proud of our antibody platforms. Read an article published in the JCO on DuoBody-CD3×CD20, a #BispecificAntibody created using DuoBody® technology with the potential to create novel therapies for lymphoma (link)
	11/9 10:25 af E L	the Camidanlumab article referred to yesterday - CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity - (link) (preclinical as gentogen correctly noted)
	11/9 08:41 af Sukkeralf	Without exaggeration, this is the most significant filing in the modern history of therapeutic developments for patients with AL amyloidosis,” Raymond L. Comenzo, MD, director of the John C. Davis Myeloma and Amyloid Program at Tufts Medical Center told OncLive.
	11/9 08:01 af bibob	Sc Dara in AL . (link)
	11/9 07:19 af Helge Larsen/PI-redaktør	TA Genmab: (link)